Matinas BioPharma
MTNB
54 hedge funds and large institutions have $41.1M invested in Matinas BioPharma in 2019 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.
399% more capital invested
Capital invested by funds: $8.24M → $41.1M (+$32.9M)
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
54% more funds holding
Funds holding: 35 → 54 (+19)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0.29% more ownership
Funds ownership: 0.25% → 0.54% (+0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.34M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$4.9M |
| 3 |
BC
Broadfin Capital
New York
|
+$2.94M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.16M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$1.08M |
| 2 |
AGM
Alpine Global Management
New York
|
-$245K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$61K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$51.7K |
| 5 |
Squarepoint
New York
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAL
51
Capital Analysts LLC
Fort Washington,
Pennsylvania
| $1K | – | – | – |
|
|
APA
52
American Portfolios Advisors
Holbrook,
New York
| $545 | +$539 | +10 | New |
|
53
BNP Paribas Financial Markets
Paris,
France
| $27 | -$5.12K | -95 | -99% |
|
|
IA
54
IFP Advisors
Tampa,
Florida
| – | -$1.08M | -35,500 | Closed |
|
|
AGM
55
Alpine Global Management
New York
| – | -$245K | -8,250 | Closed |
|
|
56
Citadel Advisors
Miami,
Florida
| – | -$61K | -2,072 | Closed |
|
|
57
Squarepoint
New York
| – | -$21K | -710 | Closed |
|
58
Invesco
Atlanta,
Georgia
| – | -$15K | -512 | Closed |
|
MTNB Hedge Fund Activity: Q1 2019 in Review
54 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2019, worth a combined $41.1M — up 399% from $8.24M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MTNB positions and 5 closed out — a net gain of 19 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $7.34M. The largest seller was IFP Advisors, exiting entirely with an estimated $1.08M sold.
- 54 institutional investors held Matinas BioPharma (MTNB) as of Q1 2019, up from 35 in Q4 2018.
- Funds reported $41.1M of Matinas BioPharma stock for Q1 2019, up 399% quarter-over-quarter.
- 24 funds opened new Matinas BioPharma positions in Q1 2019 and 5 closed out, a net change of +19 holders.
- The largest Matinas BioPharma buyer in Q1 2019 was Vivo Capital, an estimated $7.34M added.
- The largest Matinas BioPharma seller in Q1 2019 was IFP Advisors, an estimated $1.08M sold.
Based on aggregated 13F filings for Q1 2019.